LUND, Sweden, March 30, 2021 /PRNewswire/ -- Immunovia today
announced improved performance of its blood based IMMray™ PanCan-d
biomarker signature together with CA 19-9, in a clinical
retrospective study. The study was designed to evaluate detection
of early stage pancreatic cancer in high risk patients with
non-specific but concerning symptoms. The study data demonstrate
that Immunovia's test now detects pancreatic cancers (all
stages) with 92% specificity and 81% sensitivity for this cohort,
which is equivalent to results presented in the previous Commercial
Test Model Study (link to PR). Importantly, early stage PDAC I/II
were detected with specificity of 92% and sensitivity of 80%. The
improved test performance was demonstrated in a combined samples
cohort of newly collected samples and samples from the Clinical
Verification study. In total 433 samples of which 202 were PDACs
whereof 89 PDAC stage I/II and 231 symptomatic controls were
analyzed. These samples have been freshly collected from 7 sites in
the US and Europe: Beth Israel
Deaconess Medical Center, University of
Pittsburgh Medical Center, Pancreatic Cancer Center at
NYU Langone's Perlmutter Cancer Center in the US; University
College London in the UK; Sahlgrenska University Hospital in
Sweden; and University Hospital
Erlangen in Germany; and Ramón y
Cajal University Hospital, IRYCIS, CIBERONC in Spain.
Linda Mellby, PhD, VP R&D
Immunovia commented: "Detecting pancreatic cancer as early as
possible in high risk symptomatic patients is a challenging but
extremely important achievement that will support clinicians in
providing accelerated and correct diagnosis to the patients. We are
very excited to report 92% specificity and 80 % sensitivity for
detecting early stage pancreatic cancer in this risk group of
patients."
Patrik Dahlen, CEO, Immunovia
added: " These results demonstrate great performance for detection
of early stage pancreatic cancer in symptomatic cohorts, and they
further confirm the commercialization strategy for this important
risk group of patients. The market size for the symptomatic risk
group is 1-2 million patients in USA and Europe. Our test is designed to help
clinicians find the cancer at a treatable stage and thus help the
patients live longer."
Webcasted teleconference
These results will be presented Tuesday March 30, 2021, in
a webcasted teleconference at 16.30 (CET).
Presenters: Thomas King, MD, PhD, Linda Mellby, PhD, Patrik Dahlen CEO,
Immunovia
The presentations will be followed by a Q&A session. The
webcasted teleconference will be held in English.
Dial-in details:
SE: +46 856642651
US: +18558570686
UK: +44 3333000804
Pin code: 20761152#
Webcast: https://financialhearings.com/event/13801
Following the teleconference, a recording will be available on
Immunovia's website (www.immunovia.com).
This is information that Immunovia is obliged to make public
pursuant to the EU Market Abuse Regulation. The information was
submitted for publication, through the agency of the contact person
set out above, at 21:20 CET on
March 29, 2021.
For more information, please contact:
Patrik Dahlen
CEO Immunovia
Email: patrik.dahlen@immunovia.com
Tel: +46 73 376 76 64
About Immunovia
Immunovia AB is a diagnostic company that is developing and
commercializing highly accurate blood tests for the early detection
of cancer and autoimmune diseases based on Immunovia's
proprietary test platform called IMMray™. Tests are based on
antibody biomarker microarray analysis using advanced
machine-learning and bioinformatics to single-out a set of relevant
biomarkers that indicate a certain disease. Thus, forming a unique
"disease biomarker signature".
The company was founded in 2007, based on cancer studies and
ground-breaking research in the Department of Immuntechnology at
Lund University and CREATE Health
Cancer Center, Sweden.
The first product, IMMray™ PanCan-d, is undergoing clinical
evaluation in some of the world's largest clinical studies for
pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1 and is
currently in the final validation phase. The company aims for a
sales start at the end of Q1 2021 with subsequent commercial
testing in Q2.
When validated, IMMray™ PanCan-d will be the first blood-based
test for early diagnosis of pancreatic cancer on the market, with a
potential to significantly improve patient survival and
outcome.
Immunovia Dx Laboratories located in Marlborough, Massachusetts, USA and
Lund, Sweden will provide
laboratory testing services in two accredited reference
laboratories.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/immunovia-ab/r/immunovia-reports-improved-test-performance-of-immray-tm--pancan-d-in-detecting-early-stage-pancreat,c3316650
The following files are available for download:
https://mb.cision.com/Main/13121/3316650/1394676.pdf
|
Press release
(PDF)
|
View original
content:http://www.prnewswire.com/news-releases/immunovia-reports-improved-test-performance-of-immraytm-pancan-d-in-detecting-early-stage-pancreatic-cancer-in-high-risk-symptomatic-patients-301258015.html
SOURCE Immunovia AB